University Health Network Princess Margaret Cancer Center P2C
Welcome,         Profile    Billing    Logout  
 29 Trials 
50 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oza, Amit M
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
CAN-STAMP, NCT04159155: A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

Recruiting
2/3
267
Canada
External Beam Radiation, Niraparib, Zejula, Vaginal high-dose rate brachytherapy, Observation - no drugs
University Health Network, Toronto
Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
09/25
09/27
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
NCT01081951 / 2009-015970-36: Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Active, not recruiting
2
162
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, paclitaxel, Taxol, carboplatin, Drug: carboplatin
AstraZeneca
Ovarian Cancer
10/11
12/24
NCT03016338: Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active, not recruiting
2
51
Canada
Niraparib, MK4827, TSR-042, Dostarlimab
University Health Network, Toronto, Tesaro, Inc.
Endometrial Cancer
01/21
12/25
NCI-2014-00620, NCT02101775: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
124
Canada, US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/25
NEO, NCT02489006 / 2016-002573-35: A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Active, not recruiting
2
71
Europe, Canada, RoW
Olaparib, Lynparza, Platinum-based Chemotherapy
University Health Network, Toronto, AbbVie, AstraZeneca
Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical Procedures
12/25
12/25
PESCO, NCT03029403: Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruiting
2
47
Canada
Pembrolizumab, Keytruda, DPX-Survivac, Cyclophosphamide, Procytox
University Health Network, Toronto, Merck Sharp & Dohme LLC, ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
12/24
02/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT03480776: ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Active, not recruiting
2
117
Canada, RoW
Acetylsalicylic acid, ASA, Placebo
Canadian Cancer Trials Group, Apotex Inc.
Ovarian Cancer Prevention
06/25
12/25
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer
Active, not recruiting
2
125
Europe, Canada, US, RoW
Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel
Tesaro, Inc.
Ovarian Neoplasms
08/25
04/27
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
EPOCH, NCT05619913: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Recruiting
2
30
Europe, Canada, RoW
Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda
Australia New Zealand Gynaecological Oncology Group, Eisai Inc., Merck Sharp & Dohme LLC
Ovarian Carcinosarcoma, Uterine Carcinosarcoma
03/25
12/26
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Active, not recruiting
2
122
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
NCT04260802: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Recruiting
1/2
116
Canada
OC-001, Drug: OC-001 in Combination with Avelumab
Ocellaris Pharma, Inc.
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer
03/26
09/26
NCT02632448: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Recruiting
1/2
229
Europe, Canada, US, RoW
LY2880070, Gemcitabine, Gemzar
Esperas Pharma Inc.
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
09/25
09/25
CX-5461-04, NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting
1
52
Canada, US
CX-5461, Pidnarulex
Senhwa Biosciences, Inc.
Advanced Solid Tumor
12/24
06/25
Exactis-03, NCT05358639: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Active, not recruiting
1
36
Canada
Olaparib tablet, Lynparza, Navitoclax, ABT-263
Sunnybrook Health Sciences Centre, Exactis Innovation, Centre hospitalier de l'Université de Montréal (CHUM), Princess Margaret Hospital, Canada
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
03/25
04/25
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
NCT02341118: Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

Terminated
N/A
109
Canada
BRCA genetic data
University Health Network, Toronto
Ovarian Cancer
04/18
05/23
NCT06254781: Luspatercept in Metastatic AGCT of the Ovary

Completed
N/A
1
Canada
Luspatercept, Reblozyl
University Health Network, Toronto
Adult Granulosa Cell Tumor of the Ovary
08/22
08/22
NCT06328491: Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

Completed
N/A
1
Canada
Erdafitinib, Balversa
University Health Network, Toronto
Ovarian Cancer, Steroid Cell Tumor, Malignant
08/22
08/22
NCT02334761: Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.

Completed
N/A
129
Canada
University Health Network, Toronto
Pathology
12/22
12/22
RESPECT, NCT04574765: A Research Platform to Screen Healthcare Workers- Coordinated Approach to Pandemic Trials of COVID-19

Active, not recruiting
N/A
100000
Canada
Nasopharyngeal swab, Questionnaire collection, Optional blood completion, Optional questionnaire completion
University Health Network, Toronto
Healthcare Worker, Covid19
12/24
12/24
MAMBO, NCT03260647: Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers

Recruiting
N/A
150
Canada
Management algorithm for Malignant Bowel Obstruction
University Health Network, Toronto
Gynecologic Cancer
12/24
12/24
VENUS, NCT03420118: Study of Biomarkers in Gynecological Cancers

Recruiting
N/A
500
Canada
Tumour tissue collection, Blood draws
University Health Network, Toronto
Gynecologic Cancer
12/24
12/25
UNIQUE, NCT06285500: Umbrella Study for Single Patient Treatments in Oncology

Recruiting
N/A
400
Canada
Patient-specific treatments
University Health Network, Toronto
Advanced Cancer, Rare Diseases
02/27
02/29
NCT03419689: Study Looking at Biomarkers in Ovarian Cancer

Recruiting
N/A
510
Canada
Tumour tissue collection, Blood sample collection, Ascites Collection, Fluid Collection
University Health Network, Toronto
Gynecologic Cancer
06/26
06/26
Waddell, Thomas
SORT, NCT05183932: Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

Recruiting
N/A
440
Canada, US
Washington University School of Medicine, National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
01/27
01/27
Cypel, Marcelo
NCI-2018-01456, NCT03599752: Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Active, not recruiting
2
40
Canada, US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Metastasectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
01/30
01/30
NCT03112044: Lung Transplant HCV, Pilot Study

Active, not recruiting
1
26
Canada
Sofosbuvir-velpatasvir (400 mg/100 mg), Epclusa, Ex Vivo Lung Perfusion (EVLP), Normothermic EVLP
University Health Network, Toronto, Gilead Sciences
Lung Transplant Infection, Hepatitis C
01/20
12/24
NCT02811523: In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Recruiting
1
17
Canada
Doxorubicin
University Health Network, Toronto
Bone Sarcoma, Soft Tissue Sarcoma, Pulmonary Metastases
02/25
02/25
NCT05611034: In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Recruiting
1
10
Canada
Oxaliplatin
University Health Network, Toronto
Lung Metastases, Colorectal Cancer Metastatic, Colorectal Cancer
01/27
01/32
NCT04616365: Planned Semi-Elective Lung Tx Study

Completed
N/A
70
Europe, Canada
Semi-Elective Lung Transplantation
University Health Network, Toronto
Lung Transplantation
04/22
04/23
ULTIMATE, NCT04832789: Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO

Not yet recruiting
N/A
72
Canada, US
Venovenous ECMO
University of Toronto, University Health Network, Toronto
ARDS
06/23
12/23
REVOLUTION, NCT06615492: Routine vs On-demand ECMO for Lung Transplantation

Not yet recruiting
N/A
218
Canada
Routine ECMO, On-demand ECMO
Centre hospitalier de l'Université de Montréal (CHUM)
Respiratory Failure, Interstitial Lung Disease (ILD), Pulmonary Fibrosis, COPD (Chronic Obstructive Pulmonary Disease)
10/28
12/28
NCT05898776: 10°C Vs 4°C Lung Preservation RCT

Recruiting
N/A
300
Europe, Canada, US, RoW
Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation
University Health Network, Toronto, Medical University of Vienna, Vanderbilt University, Puerta de Hierro University Hospital, University of California, San Francisco, Centre Hospitalier Universitaire Vaudois, Mayo Clinic, St Vincent's Hospital, Sydney
Lung Transplant, Organ Preservation
07/25
07/26
Lister, Jennifer
STABLE-MATES, NCT02468024: JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Recruiting
3
272
Europe, Canada, US, RoW
Lung Surgery, SR, Radiation therapy, SAbR
University of Texas Southwestern Medical Center
Non-Small Cell Lung Cancer
12/28
12/28
PACT, NCT03848312: Preventing Alzheimer's With Cognitive Training

Recruiting
3
7600
US
Cognitive Training, Computerized Cognitive Stimulation
University of South Florida, National Institute on Aging (NIA)
Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
01/26
01/26
POWERRANGER, NCT01404156: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma

Completed
2/3
29
Canada
(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, ECF/ECX or FLOT, Carboplatin paclitaxel plus concurrent radiotherapy
Dr. Gordon Buduhan, CancerCare Manitoba, University of Toronto, London Health Sciences Centre
Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
08/23
08/23
NCI-2018-01456, NCT03599752: Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Active, not recruiting
2
40
Canada, US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Metastasectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
01/30
01/30
NCT05611034: In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

Recruiting
1
10
Canada
Oxaliplatin
University Health Network, Toronto
Lung Metastases, Colorectal Cancer Metastatic, Colorectal Cancer
01/27
01/32
NCT03265379: Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection

Recruiting
N/A
104
Canada
FACT-B and Brief Pain Inventory
University Health Network, Toronto
Breast Cancer
08/30
08/30
Antonoff, Mara
NCI-2018-01456, NCT03599752: Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Active, not recruiting
2
40
Canada, US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Metastasectomy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
01/30
01/30
NCT06196008: Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Recruiting
N/A
382
US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Physical Fitness Testing, Physical Function Testing, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Lung Carcinoma
05/28
05/28
NCT03802981: A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)

Active, not recruiting
N/A
338
Canada, US
Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, Brigham and Women's Hospital, Duke University, Mayo Clinic, Université de Montréal, University of Pittsburgh, University of Toronto, Washington University School of Medicine
Multiple Ground Glass Opacities (GGOs)
01/26
01/26
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Recruiting
N/A
8300
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
09/26
09/26

Download Options